Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology
June 26th, 2007
Abbott (NYSE: ABT) and Genentech, Inc. (NYSE: DNA) have formed acollaboration for the global research, development andcommercialization of two of Abbott’s investigational anti-cancercompounds. The companies will work together on all aspects offurther development and commercialization of ABT-263 and ABT-869,which were discovered by Abbott scientists.